Some leading hospitals have already started experimenting with deep learning based AI that applies most directly to medical imaging. In a few years, we will be taking many more uses of AI for granted. How does the healthcare industry get from here to there?
MHE's Briana Contreras spoke with Amy Dirks Stevens, EVP of Digital Strategy Performance and Practice Lead at AVIA health, for this week's episode of Tuning Into the C-Suite. The two talked about automation in health systems and how it can be a solution to challenges such as budget issues and creating more efficiency in the workplace. Also discussed were areas where health system leaders can begin to leverage artificial intelligence.
If the boom in new C-suite titles in healthcare — such as chief experience officer, chief growth officer, and chief analytics officer — “reflect new priorities and cultural shifts” inside organizations, what new titles should we be on the lookout for in the year ahead?
The subsidiary, called Vivid Clear Rx, will provide PBM services to help the company's 88,000 employees better manage their healthcare costs.
CVS and Walgreens are poised to vaccinate residents and employees of long-term care facilities. Dentists and optometrists are angling to be among the healthcare professionals who could administer the COVID-19 vaccines.
As the world remains battling the coronavirus pandemic, there are still significant and unmet needs for those fighting chronic conditions and disorders like opioid use disorder (OUD).
COVID-19 pandemic may present an opportunity to hit a reset button on American healthcare that could winnow out unnecessary, wasteful services and prescriptions.
New Mexico Gov. Michelle Lujan Grisham and former Surgeon General Vivek Murthy appear to be the frontrunners for HHS secretary in the Biden administration.
FDA okayed the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen positive lesions in men with prostate cancer.
Nearly two-thirds of U.S. patients are likely to switch to a new healthcare provider if their current health provider doesn’t meet their expectations for managing COVID-19 concerns.
The drug is the first FDA-approved therapy for these rare genetic diseases.
In a time of lockdowns and concerted efforts to avoid exposure to COVID-19, telehealth is not only the hottest topic in healthcare, but also a boon to providers attempting to treat behavioral health patients in a holistic and cost-effective way.
The continuous battle in cancer research has unfortunately fallen a bit to the backseat due to healthcare's main focus on beating COVID-19 wildfires. To bring its needed attention back up on the ladder, Marie Lamont, president and COO of Inteliquet, a clinical trial software company, shares what took place in the drop of oncology-related activity and what can be done to improve.
Customer experience is everything, especially for healthcare businesses. However, there seems to be a gap between healthcare providers and their consumers.
FDA approves several drugs to treat rare conditions in both cancer and metabolic diseases.
For medical professionals, COVID-19 has amplified the importance of following the evidence.
Results of APOLLO and REACH3 trials are scheduled for presentation at the American Society of Hematology meeting next month are expected to garner attention.
Public health policies and treatment advances have made a difference.
Radiation oncologists across the country met virtually with members of Congress last week to urge lawmakers to pass legislation that will safeguard access to high-quality, value-based healthcare for people with cancer.
The second of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.
Applying lessons from behavioral economics, health systems are using “nudges” to influence the choices clinicians make.
COVID-19 has amplified the growing importance of advanced practice providers as demands for healthcare increase and a national physician shortage looms.
The first of a two-part story on 10 takeaways about the telehealth boom. The COVID-19 pandemic has been a bumpy ride in the U.S., featuring one controversy after another. One of the few areas of agreement is that the widespread adoption of telehealth amid the pandemic has been, by and large, a positive development.
In this week’s episode, MHE's Briana Contreras spoke with Anthony Gabriel, M.D., MBA, chief operating officer at Radiology Partners. Anthony shared the importance of health entities having physicians in the C-Suite, or executive levels in their health organizations, as Radiology Partners does. He and Briana also discussed what type of training a health professional needs to get to this level and some decisions he’s made as a health professional in the C-Suite.
Like a marathon with runners you don't know who will come in first until the end, health plans and providers share a similarity when they look at all the patients/members whose chronic conditions have taken a back seat to battling the COVID-19 pandemic.
There’s some skepticism as programs to address social determinants of health proliferate. Some data are being collected.
Therapies that target lung cancer at the molecular level are proliferating — and so are the biomarkers for guiding their use.
FDA official says the approval is important because of the combination of the flu season and the COVID-19 pandemic.
Regeneron's investigational treatment was administered to President Donald Trump in October when he was treated for COVID-19.
